NICE reiterates that people with mild Alzheimer’s disease should not get drug treatment
BMJ 2009; 338 doi: http://dx.doi.org/10.1136/bmj.b2413 (Published 12 June 2009) Cite this as: BMJ 2009;338:b2413
Get access to this article and to all of thebmj.com for 14 days
Sign up today for a 14 day free trial
Access to the full version of this article requires a subscription
Please login, sign up for a 14 day trial, or subscribe below.
- Clare Dyer
- 1BMJ
The hopes of people with mild Alzheimer’s disease have been dashed again by the agency that appraises treatments for use by the NHS in England and Wales, which has reaffirmed its original decision to deny them treatment with dementia drugs.
The National Institute for Health and Clinical Excellence (NICE) has issued amended guidance but still asserts that the drugs would not be cost effective for the mild stages of the disease.
The original guidance from NICE was challenged by Eisai, the UK licence holder for donepezil (Aricept), one of the class of acetylcholinesterase inhibitors affected.
The Court …
Get access to this article and to all of thebmj.com for 14 days
Sign up today for a 14 day free trial
Access to the full version of this article requires a subscription
Please login, sign up for a 14 day trial, or subscribe below.
Sign in
Log in using your username and password
Log in through your institution
Free trial
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial